This Week
  • High-end project is underway in Perinton.

  • Pride in ownership is the foundation of the H&C Tool Supply Corp.

  • The new edition of Explore Greater Rochester is here.

  • Sheldon Shear and Robert Cherry followed in their dads' footsteps at Economy Paper.

  • With falling prices, are commodities a bargain investment or a risky bet?

  • John Johnson introduced software to help guide Baldwin Richardson Foods Co.

Reports: Bausch & Lomb close to being acquired

Rochester Business Journal
May 24, 2013

Canada’s largest drugmaker is close to acquiring Bausch & Lomb Inc. in a roughly $9 billion deal, published reports state.

Valeant Pharmaceuticals International Inc. is seeking to acquire the local eye-care company owned by private-equity firm Warburg Pincus LLC, Bloomberg, Reuters and the Wall Street Journal reported Friday afternoon.
Warburg reportedly had been shopping Bausch & Lomb to a variety of companies early this year, and then filed for an initial public offering in March after the effort to sell the company for at least $10 billion stalled.

Valeant is seeking acquisitions of companies with solid cash flows in high-growth areas, CEO Mike Pearson said on a conference call with investors earlier this month, Bloomberg reported. The Bausch & Lomb deal would be the largest of 15 acquisitions for Montreal-based Valeant since it was created in a 2010 merger of its U.S. predecessor and Canada’s Biovail Corp.

Private equity firm Warburg Pincus bought Bausch & Lomb for $3.7 billion in September 2007, taking the longtime publicly traded company private.

Bausch & Lomb officials have declined to talk about possible acquisitions of the company.

In an interview with the Rochester Business Journal last July, Bausch & Lomb CEO Brent Saunders said an IPO was more likely than a sale.

The company has posted a loss in each of the last three years, the registration filing states. Its net losses in 2010-2012 attributable to Bausch & Lomb Holdings were $196 million, $123.9 million and $68.3 million, respectively.

Net sales rose from $937.2 million in 2010 to $1.3 billion in 2012.

Bloomberg projected that at $9 billion including debt, Bausch & Lomb would be valued at about 21 times earnings before interest, taxes, depreciation and amortization of $429.5 million in the year through December.
5/24/13 (c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or email

What You're Saying 

There are no comments yet. Be the first to add yours!

Post Your Own Comment


Not registered? Sign up now!

To Do   Text Size
Post CommentPost A Comment eMail Size1
View CommentsView All Comments PrintPrint Size2
ReprintsReprints Size3
  • E-mailed
  • Commented
  • Viewed
RBJ   Google